Iakoubova Olga A, Tong Carmen H, Chokkalingam Anand P, Rowland Charles M, Kirchgessner Todd G, Louie Judy Z, Ploughman Lynn M, Sabatine Marc S, Campos Hannia, Catanese Joseph J, Leong Diane U, Young Bradford A, Lew David, Tsuchihashi Zenta, Luke May M, Packard Christopher J, Zerba Kim E, Shaw Peter M, Shepherd James, Devlin James J, Sacks Frank M
Celera Inc, 1401 Harbor Bay Parkway, Alameda, CA 94502, USA.
Arterioscler Thromb Vasc Biol. 2006 Dec;26(12):2763-8. doi: 10.1161/01.ATV.0000247248.76409.8b. Epub 2006 Sep 28.
Statins reduce inflammation and risk of myocardial infarction (MI). Because the myeloid IgA Fc receptor encoded by FCAR mediates inflammation, we hypothesized that the FCAR Asp92Asn polymorphism is associated with risk of MI and that this risk would be modified by pravastatin.
In the placebo arm of the Cholesterol and Recurrent Events (CARE) study, male carriers of the 92Asn allele had an adjusted hazard ratio for incident MI of 1.68 (95% CI 1.10 to 2.57); relative risk reduction by pravastatin was 69% in carriers and 12% in noncarriers (P(interaction)=0.007). In the placebo arm of the all-male West of Scotland Coronary Prevention Study (WOSCOPS), carriers had an adjusted odds ratio for incident coronary heart disease (CHD) of 1.46 (90% CI 1.05 to 2.03); for pravastatin compared with placebo treatment, the adjusted odds ratios were 0.55 (95% CI 0.32 to 0.93) in carriers and 0.65 (95% CI 0.51 to 0.83) in noncarriers (P(interaction)=0.55).
Carriers of 92Asn had increased risk of MI in CARE and increased odds of CHD in WOSCOPS. Pravastatin significantly reduced risk in carriers in both CARE and WOSCOPS. A genotype by treatment interaction was observed in CARE but not in WOSCOPS.
他汀类药物可减轻炎症并降低心肌梗死（MI）风险。由于由FCAR编码的髓样IgA Fc受体介导炎症，我们推测FCAR Asp92Asn多态性与MI风险相关，且普伐他汀可改变这种风险。
在胆固醇与再发事件（CARE）研究的安慰剂组中，92Asn等位基因的男性携带者发生MI的校正风险比为1.68（95%可信区间1.10至2.57）；普伐他汀使携带者的相对风险降低69%，非携带者降低12%（交互作用P=0.007）。在全男性的苏格兰西部冠心病预防研究（WOSCOPS）的安慰剂组中，携带者发生冠心病（CHD）的校正比值比为1.46（90%可信区间1.05至2.03）；与安慰剂治疗相比，普伐他汀治疗时，携带者的校正比值比为0.55（95%可信区间0.32至0.93），非携带者为0.65（95%可信区间0.51至0.83）（交互作用P=0.55）。
在CARE研究中92Asn携带者发生MI风险增加，在WOSCOPS研究中发生CHD几率增加。在CARE和WOSCOPS研究中，普伐他汀均显著降低了携带者的风险。在CARE研究中观察到了基因型与治疗的交互作用，而在WOSCOPS研究中未观察到。
